New cell therapy shows promise for tough-to-treat lymphoma

NCT ID NCT06561425

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study tests an experimental treatment called GLPG5101 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. The treatment is a cell therapy made at the hospital. The study has two phases: first, finding the best dose with the fewest side effects; second, checking how well that dose works. About 130 participants will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Academisch Medisch Centrum (Amsterdam UMC)

    Amsterdam, 1105 AZ, Netherlands

  • Algemeen Ziekenhuis Delta

    Roeselare, 8800, Belgium

  • Antwerp University Hospital

    Edegem, 2650, Belgium

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • CHU De Liège

    Liège, 4000, Belgium

  • Cliniques Universitaires Saint-Luc

    Woluwe-Saint-Lambert, 1200, Belgium

  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

    Rotterdam, 3015 GD, Netherlands

  • Helsingin Yliopistollinen Sairaala (HUS)

    Helsinki, 00029, Finland

  • Leiden University Medical Center

    Leiden, 2333 ZA, Netherlands

  • Tufts Medical Center

    Boston, Massachusetts, 02111, United States

  • UZ Leuven

    Leuven, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.